In vivo detection of amyloid deposits is useful for early diagnosis of Alzheimer's disease (AD) and for prediction of potential converters from mild cognitive impairment (MCI) to AD. Our original imaging probe, [ 11C]BF-227, has been shown to be useful for clinical evaluation of AD, MCI and various neurodegenerative disorders using positron emission tomography (PET). Purpose of the present study is to examine methods for quantitative analysis of amyloid deposition in human brain using PET and [ 11C]BF-227 as well as our newer compound [18F]FACT. For [11C]BF-227, six AD patients (mean age: 73.0 y.o.) and six healthy controls (mean age: 61.3 y.o.) were studied. For [18F]FACT, ten AD patients (mean age: 74.5 y.o.) and six healthy controls (mean age: 68.3 y.o.) were studied in the present study. Regions of interest (ROIs) were placed on various cortical and subcortical regions in dynamic PET images of 60- min- and 90-min-long duration, based on the coregistered MRI T1 images. Results of quantification using arterial inputs were compared to those calculated by Logan graphical analysis with arterial data (LGA) and with the reference data (LGAR), and to those calculated by full kinetic analysis based on 1- and 2- tissue compartmental models (1TM and 2TM). These results were compared to the ratio of standardized uptake values (SUV) in the cortex to that in the cerebellum, as well. [11C]BF-227 displayed significantly higher distribution volume ratio (DVR) values in AD patients than in controls in various cortical regions such as the cingulate, temporal and occipital regions, especially in the temporo-occipital regions. The preliminary results of quantitative analysis of [18F]FACT showed nearly the same findings as those of [ 11C]BF-227. Considering the longer half-life of 18F nuclide (110 min) than that of 11C nuclide (20 min), this tracer could be used as a diagnosing pharmaceutical for delivery.